Select acquires remainder of subsidiaries
By Melissa Trudinger
Tuesday, 30 November, 2004
Tuesday, 30 November, 2004
Select Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.
The institute will be issued 4 million new shares plus 2 million options in Select Vaccines in return for its equity.
Ongoing R&D programs being conducted by the Burnet Institute for the two companies will continue to be funded through December 2005.
Related News
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
